MolPharm xPharm- The Comprehensive Pharmacology Reference

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by YAMADA, S.
Right arrow Articles by ROESKE, W. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by YAMADA, S.
Right arrow Articles by ROESKE, W. R.

Molecular Pharmacology, Vol 18, 185-192, Copyright © 1980 by the American Society for Pharmacology and Experimental Therapeutics

Alterations in Cardiac Autonomic Receptors following 6-Hydroxydopamine Treatment in Rats

SHIZUO YAMADA 1, HENRY I. YAMAMURA 1, and WILLIAM R. ROESKE 1

1 Departments of Internal Medicine, Psychiatry and Pharmacology, University of Arizona, Arizona Health Sciences Center, Tucson, Arizona 85724

To characterize the regional changes in beta-adrenergic and muscarinic cholinergic receptors in rat hearts following 6-hydroxydopamine (6-OHDA) treatment, receptor binding assays using the specific ligands [3H]dihydroalprenolol (DHA) (beta-adrenergic receptor) and [3H]quinuclidinyl benzilate (QNB) (muscarinic cholinergic receptor) were performed in five regions of control and treated hearts. In addition, norepinephrine (NE) concentration and choline acetyltransferase activity in hearts were assayed to characterize the model. Rats were treated with 2 x 50 mg/kg i.v. injections of 6-OHDA . HBr at 24-h intervals and the hearts were removed 1, 2, and 3 weeks later. The specific [3H]DHA binding was significantly higher in the ventricles and intraventricular septum than in the right atria of control rat hearts, suggesting a regional variation for beta-adrenergic receptors. Following 6-OHDA treatment, the specific [3H]DHA binding to right atria, left ventricles, and ventricular septae significantly increased compared to similar regions of control rat hearts. The Bmax value in left ventricles was significantly increased, by 32, 38, and 17%, respectively, at 1, 2, and 3 weeks without a change in the Kd, suggesting an increase in the density of beta-adrenergic receptors. There was a marked (60-80%) reduction of NE levels in all regions of 6-OHDA-treated rat hearts. These results suggest a relationship between the reduction of endogenous NE and the development of the increased density of beta-adrenergic receptors in the rat hearts following 6-OHDA treatment. Specific [3H]QNB binding was significantly higher in atria than in ventricles of control rat hearts. The binding to each region was unchanged at 1 and 2 weeks following 6-OHDA treatment, while it was significantly increased in most regions at 3 weeks. There was a 30% increase in the Bmax in right and left atria without a change in the Kd, suggesting a change in the receptor density. The choline acetyltransferase activity was not significantly altered in any region of 6-OHDA-treated rat hearts. The present study has demonstrated that destruction of noradrenergic nerve terminals in rats with 6-OHDA leads to an increase in the density of beta-adrenergic receptors and a decrease in the NE concentration and that most of the cardiac muscarinic cholinergic receptors are not located on adrenergic neurons.

Note:
ACKNOWLEDGMENTS The authors would like to express their appreciation to Ms. Judy Hurley and to Ms. Carol Corelis for secretarial assistance in typing the manuscript. The authors would like to express their appreciation to Prof. E. Hayashi, Department of Pharmacology, Shizuoka College of Pharmaceutical Sciences, Shizuoka, Japan, for providing S. Yamada with the opportunity to work on this project.

Submitted on November 19, 1979
Accepted on March 19, 1980




This article has been cited by other articles:


Home page
J. Appl. Physiol.Home page
P. Barbe, J. Galitzky, C. Thalamas, D. Langin, M. Lafontan, J. M. Senard, and M. Berlan
Increase in epinephrine-induced responsiveness during microgravity simulated by head-down bed rest in humans
J Appl Physiol, November 1, 1999; 87(5): 1614 - 1620.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
P. Barbe, J. Galitzky, I. De Glisezinski, D. Riviere, C. Thalamas, J. M. Senard, F. Crampes, M. Lafontan, and M. Berlan
Simulated Microgravity Increases {beta}-Adrenergic Lipolysis in Human Adipose Tissue
J. Clin. Endocrinol. Metab., February 1, 1998; 83(2): 619 - 625.
[Abstract] [Full Text]


Home page
J. Pharmacol. Exp. Ther.Home page
I. Kovacs, H. I. Yamamura, S. L. Waite, E. V. Varga, and W. R. Roeske
Pharmacological Comparison of the Cloned Human and Rat M2 Muscarinic Receptor Genes Expressed in the Murine Fibroblast (B82) Cell Line
J. Pharmacol. Exp. Ther., February 1, 1998; 284(2): 500 - 507.
[Abstract] [Full Text]


Home page
J. Pharmacol. Exp. Ther.Home page
S. Yamada, T. Ohkura, T. Yamadera, O. Ito, R. Kimura, Y. Nozawa, S. Hayashi, and H. Miyake
Abnormality in Plasma Catecholamines and Myocardial Adrenoceptors in Cardiomyopathic BIO 53.58 Syrian Hamsters and Improvement by Metoprolol Treatment
J. Pharmacol. Exp. Ther., December 1, 1997; 283(3): 1389 - 1395.
[Abstract] [Full Text]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 1980 by the American Society for Pharmacology and Experimental Therapeutics